Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

Prakash Jagtap, Csaba Szabo

Research output: Contribution to journalArticle

657 Citations (Scopus)

Abstract

Poly(ADP-ribose) polymerases (PARPs) are involved in the regulation of many cellular functions. Three consequences of the activation of PARP1, which is the main isoform of the PARP family, are particularly important for drug development: first, its role in DNA repair; second, its capacity to deplete cellular energetic pools, which culminates in cell dysfunction and necrosis; and third, its capacity to promote the transcription of pro-inflammatory genes. Consequently, pharmacological inhibitors of PARP have the potential to enhance the cytotoxicity of certain DNA-damaging anticancer drugs, reduce parenchymal cell necrosis (for example, in stroke or myocardial infarction) and downregulate multiple simultaneous pathways of inflammation and tissue injury (for example, in circulatory shock, colitis or diabetic complications). The first ultrapotent novel PARP inhibitors have now entered human clinical trials. This article presents an overview of the principal pathophysiological pathways and mechanisms that are governed by PARP, followed by the main structures and therapeutic actions of various classes of novel PARP inhibitors.

Original languageEnglish (US)
Pages (from-to)421-440
Number of pages20
JournalNature Reviews Drug Discovery
Volume4
Issue number5
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Therapeutic Uses
Necrosis
Diabetes Complications
Colitis
DNA Repair
Pharmaceutical Preparations
Shock
Protein Isoforms
Down-Regulation
Stroke
Myocardial Infarction
Clinical Trials
Pharmacology
Inflammation
DNA
Wounds and Injuries
Genes
Poly(ADP-ribose) Polymerase Inhibitors
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. / Jagtap, Prakash; Szabo, Csaba.

In: Nature Reviews Drug Discovery, Vol. 4, No. 5, 05.2005, p. 421-440.

Research output: Contribution to journalArticle

@article{a10b6deb409b4fc7bea48a5013168767,
title = "Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors",
abstract = "Poly(ADP-ribose) polymerases (PARPs) are involved in the regulation of many cellular functions. Three consequences of the activation of PARP1, which is the main isoform of the PARP family, are particularly important for drug development: first, its role in DNA repair; second, its capacity to deplete cellular energetic pools, which culminates in cell dysfunction and necrosis; and third, its capacity to promote the transcription of pro-inflammatory genes. Consequently, pharmacological inhibitors of PARP have the potential to enhance the cytotoxicity of certain DNA-damaging anticancer drugs, reduce parenchymal cell necrosis (for example, in stroke or myocardial infarction) and downregulate multiple simultaneous pathways of inflammation and tissue injury (for example, in circulatory shock, colitis or diabetic complications). The first ultrapotent novel PARP inhibitors have now entered human clinical trials. This article presents an overview of the principal pathophysiological pathways and mechanisms that are governed by PARP, followed by the main structures and therapeutic actions of various classes of novel PARP inhibitors.",
author = "Prakash Jagtap and Csaba Szabo",
year = "2005",
month = "5",
doi = "10.1038/nrd1718",
language = "English (US)",
volume = "4",
pages = "421--440",
journal = "Nature Reviews Drug Discovery",
issn = "1474-1776",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

AU - Jagtap, Prakash

AU - Szabo, Csaba

PY - 2005/5

Y1 - 2005/5

N2 - Poly(ADP-ribose) polymerases (PARPs) are involved in the regulation of many cellular functions. Three consequences of the activation of PARP1, which is the main isoform of the PARP family, are particularly important for drug development: first, its role in DNA repair; second, its capacity to deplete cellular energetic pools, which culminates in cell dysfunction and necrosis; and third, its capacity to promote the transcription of pro-inflammatory genes. Consequently, pharmacological inhibitors of PARP have the potential to enhance the cytotoxicity of certain DNA-damaging anticancer drugs, reduce parenchymal cell necrosis (for example, in stroke or myocardial infarction) and downregulate multiple simultaneous pathways of inflammation and tissue injury (for example, in circulatory shock, colitis or diabetic complications). The first ultrapotent novel PARP inhibitors have now entered human clinical trials. This article presents an overview of the principal pathophysiological pathways and mechanisms that are governed by PARP, followed by the main structures and therapeutic actions of various classes of novel PARP inhibitors.

AB - Poly(ADP-ribose) polymerases (PARPs) are involved in the regulation of many cellular functions. Three consequences of the activation of PARP1, which is the main isoform of the PARP family, are particularly important for drug development: first, its role in DNA repair; second, its capacity to deplete cellular energetic pools, which culminates in cell dysfunction and necrosis; and third, its capacity to promote the transcription of pro-inflammatory genes. Consequently, pharmacological inhibitors of PARP have the potential to enhance the cytotoxicity of certain DNA-damaging anticancer drugs, reduce parenchymal cell necrosis (for example, in stroke or myocardial infarction) and downregulate multiple simultaneous pathways of inflammation and tissue injury (for example, in circulatory shock, colitis or diabetic complications). The first ultrapotent novel PARP inhibitors have now entered human clinical trials. This article presents an overview of the principal pathophysiological pathways and mechanisms that are governed by PARP, followed by the main structures and therapeutic actions of various classes of novel PARP inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=18944390248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18944390248&partnerID=8YFLogxK

U2 - 10.1038/nrd1718

DO - 10.1038/nrd1718

M3 - Article

VL - 4

SP - 421

EP - 440

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

SN - 1474-1776

IS - 5

ER -